Vicore Pharma Holding AB
STO:VICO

Watchlist Manager

Vicore Pharma Holding AB

STO:VICO

Watchlist

Dividends

Discount Rate

Price: 8.19 SEK 2.12% Market Closed

Market Cap: 1.9B SEK

Have any thoughts about
Vicore Pharma Holding AB?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Estee Lauder Companies Inc NYSE:EL	Consumer products
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Church & Dwight Co Inc NYSE:CHD	Consumer products
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	American Express Co NYSE:AXP	Financial Services
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Target Corp NYSE:TGT	Retail
US	Walt Disney Co NYSE:DIS	Media
US	Mueller Industries Inc NYSE:MLI	Machinery
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 8.19 SEK

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

VICO Alert

Vicore Pharma Holding AB

8.19

+0.17 (+2.12%)

52 Week Range	6.9665 23.3
Price Target

We'll email you a reminder when the closing price reaches SEK.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Estee Lauder Companies Inc NYSE:EL	US
	Exxon Mobil Corp NYSE:XOM	US
	Church & Dwight Co Inc NYSE:CHD	US
	Pfizer Inc NYSE:PFE	US
	American Express Co NYSE:AXP	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Target Corp NYSE:TGT	US
	Walt Disney Co NYSE:DIS	US
	Mueller Industries Inc NYSE:MLI	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Vicore Pharma Holding AB

What unique competitive advantages
does Vicore Pharma Holding AB hold over its rivals?

What risks and challenges
does Vicore Pharma Holding AB face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Vicore Pharma Holding AB.

What unique competitive advantages
does Vicore Pharma Holding AB hold over its rivals?

What risks and challenges
does Vicore Pharma Holding AB face in the near future?

Has there been any significant insider trading activity
in Vicore Pharma Holding AB recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Vicore Pharma Holding AB.

Provide P/S
for Vicore Pharma Holding AB.

Provide P/E
for Vicore Pharma Holding AB.

Provide P/OCF
for Vicore Pharma Holding AB.

Provide P/FCFE
for Vicore Pharma Holding AB.

Provide P/B
for Vicore Pharma Holding AB.

Provide EV/S
for Vicore Pharma Holding AB.

Provide EV/GP
for Vicore Pharma Holding AB.

Provide EV/EBITDA
for Vicore Pharma Holding AB.

Provide EV/EBIT
for Vicore Pharma Holding AB.

Provide EV/OCF
for Vicore Pharma Holding AB.

Provide EV/FCFF
for Vicore Pharma Holding AB.

Provide EV/IC
for Vicore Pharma Holding AB.

Show me price targets
for Vicore Pharma Holding AB made by professional analysts.

What are the Revenue projections
for Vicore Pharma Holding AB?

How accurate were the past Revenue estimates
for Vicore Pharma Holding AB?

What are the Net Income projections
for Vicore Pharma Holding AB?

How accurate were the past Net Income estimates
for Vicore Pharma Holding AB?

What are the EPS projections
for Vicore Pharma Holding AB?

How accurate were the past EPS estimates
for Vicore Pharma Holding AB?

What are the EBIT projections
for Vicore Pharma Holding AB?

How accurate were the past EBIT estimates
for Vicore Pharma Holding AB?

Compare the revenue forecasts
for Vicore Pharma Holding AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Vicore Pharma Holding AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Vicore Pharma Holding AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Vicore Pharma Holding AB compared to its peers.

Compare the P/E ratios
of Vicore Pharma Holding AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Vicore Pharma Holding AB with its peers.

Analyze the financial leverage
of Vicore Pharma Holding AB compared to its main competitors.

Show all profitability ratios
for Vicore Pharma Holding AB.

Provide ROE
for Vicore Pharma Holding AB.

Provide ROA
for Vicore Pharma Holding AB.

Provide ROIC
for Vicore Pharma Holding AB.

Provide ROCE
for Vicore Pharma Holding AB.

Provide Gross Margin
for Vicore Pharma Holding AB.

Provide Operating Margin
for Vicore Pharma Holding AB.

Provide Net Margin
for Vicore Pharma Holding AB.

Provide FCF Margin
for Vicore Pharma Holding AB.

Show all solvency ratios
for Vicore Pharma Holding AB.

Provide D/E Ratio
for Vicore Pharma Holding AB.

Provide D/A Ratio
for Vicore Pharma Holding AB.

Provide Interest Coverage Ratio
for Vicore Pharma Holding AB.

Provide Altman Z-Score Ratio
for Vicore Pharma Holding AB.

Provide Quick Ratio
for Vicore Pharma Holding AB.

Provide Current Ratio
for Vicore Pharma Holding AB.

Provide Cash Ratio
for Vicore Pharma Holding AB.

What is the historical Revenue growth
over the last 5 years for Vicore Pharma Holding AB?

What is the historical Net Income growth
over the last 5 years for Vicore Pharma Holding AB?

What is the current Free Cash Flow
of Vicore Pharma Holding AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Vicore Pharma Holding AB.

VICO

Balance Sheet

Total Liabilities & Equity

Vicore Pharma Holding AB
Total Liabilities & Equity

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

Adjust for Inflation

Vicore Pharma Holding AB
Total Liabilities & Equity Peer Comparison

Comparables:

BIOG B

BONEX

VITR

SOBI

BIOA B

Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors

	Total Liabilities & Equity	CAGR 3Y	CAGR 5Y	CAGR 10Y
Vicore Pharma Holding AB STO:VICO	Total Liabilities & Equity kr478.7m	CAGR 3-Years -8%	CAGR 5-Years 12%	CAGR 10-Years N/A
Biogaia AB STO:BIOG B	Total Liabilities & Equity kr2.3B	CAGR 3-Years 7%	CAGR 5-Years 29%	CAGR 10-Years N/A
Bonesupport Holding AB STO:BONEX	Total Liabilities & Equity kr778.7m	CAGR 3-Years 31%	CAGR 5-Years 28%	CAGR 10-Years N/A
Vitrolife AB STO:VITR	Total Liabilities & Equity kr16.9B	CAGR 3-Years 40%	CAGR 5-Years 52%	CAGR 10-Years 41%
Swedish Orphan Biovitrum AB (publ) STO:SOBI	Total Liabilities & Equity kr72.2B	CAGR 3-Years 16%	CAGR 5-Years 17%	CAGR 10-Years 27%
BioArctic AB STO:BIOA B	Total Liabilities & Equity kr1.2B	CAGR 3-Years 4%	CAGR 5-Years -3%	CAGR 10-Years N/A

What is Vicore Pharma Holding AB's Total Liabilities & Equity?

Total Liabilities & Equity
478.7m SEK

Based on the financial report for Jun 30, 2024, Vicore Pharma Holding AB's Total Liabilities & Equity amounts to 478.7m SEK.

What is Vicore Pharma Holding AB's Total Liabilities & Equity growth rate?

Total Liabilities & Equity CAGR 5Y
12%

Over the last year, the Total Liabilities & Equity growth was 41%. The average annual Total Liabilities & Equity growth rates for Vicore Pharma Holding AB have been -8% over the past three years , 12% over the past five years .

Vicore Pharma Holding AB
STO:VICO

Vicore Pharma Holding AB
Total Liabilities & Equity

Vicore Pharma Holding AB
Total Liabilities & Equity Peer Comparison

Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors

See Also

What is Vicore Pharma Holding AB's Total Liabilities & Equity?

Total Liabilities & Equity
478.7m SEK

What is Vicore Pharma Holding AB's Total Liabilities & Equity growth rate?

Total Liabilities & Equity CAGR 5Y
12%

Company

Help

Tools

Stocks

Vicore Pharma Holding AB STO:VICO

Vicore Pharma Holding AB Total Liabilities & Equity

Vicore Pharma Holding AB Total Liabilities & Equity Peer Comparison

Competitive Total Liabilities & Equity Analysis Latest Figures & CAGR of Competitors

See Also

What is Vicore Pharma Holding AB's Total Liabilities & Equity? Total Liabilities & Equity 478.7m SEK

What is Vicore Pharma Holding AB's Total Liabilities & Equity growth rate? Total Liabilities & Equity CAGR 5Y 12%

Company

Help

Tools

Stocks

Vicore Pharma Holding AB
STO:VICO

Vicore Pharma Holding AB
Total Liabilities & Equity

Vicore Pharma Holding AB
Total Liabilities & Equity Peer Comparison

Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors

What is Vicore Pharma Holding AB's Total Liabilities & Equity?

Total Liabilities & Equity
478.7m SEK

What is Vicore Pharma Holding AB's Total Liabilities & Equity growth rate?

Total Liabilities & Equity CAGR 5Y
12%